Ulcerative Colitis

Erica Brenner, MD: The Success of the SECURE-IBD Database

August 13, 2020


An expert discusses how a registry of gastrointestinal symptoms is leading research during COVID-19.

Erica Brenner, MD: What We've Learned about IBD Patients with COVID-19

August 13, 2020


A gastroenterologist discusses some of the findings regarding COVID-19 and gastrointestinal symptoms.

SER-287 Shows Efficacy in Treating Ulcerative Colitis in Early Phase Trial

August 05, 2020


Firmicutes bacteria can help produce metabolites that maintain intestinal barriers and mucosal immunity.

Miguel Regueiro, MD: Ongoing Examination at Link Between Gastrointestinal Symptoms and COVID-19

July 31, 2020


Nearly two-thirds of COVID-19 patients have gastrointestinal symptoms.

Multidisciplinary Approach Beneficial for Functional Gastrointestinal Disorders

July 16, 2020


Patients in the multidisciplinary-care group were more likely to experience a 50% or higher reduction in all Gastrointestinal Symptom Severity Index symptom clusters than the patients who were in the standard-care group.

Laparoscopic Ileocecal Resection Comparable to Anti-TNF's for Crohn's Disease

July 10, 2020


In a sample of patients treated with laparoscopic ileocecal resection, 42% (n = 29) of patients did not require additional Crohn’s disease-related medication, while 48% (n = 14) were given prophylactic immunomodulator therapy.

Ozanimod Could be an Alternative to Anti-TNF Drugs for Crohn's Disease

June 30, 2020


Ozanimod could soon be added to the ever growing stable of potential treatments for Crohn’s disease.

Enhanced Treatment Endpoints Leads to Lower Risk of Ulcerative Colitis Relapse

June 24, 2020


The median 12-month risk of clinical relapse in patients with MES 1 was 28.7%, while the estimated annual risk of clinical relapse in patients with a MES 0 was 13.7%.

Upadacitinib Leads to Clinical Remission in Crohn's Disease

June 16, 2020


During the induction period, patients in the treatment group had higher incidences of infections and serious infectious compared to placebo.